Rationale and design of the Anti-Xa Therapy to Lower cardiovascular events in Addition to standard therapy in Subjects with Acute Coronary Syndrome–Thrombolysis in Myocardial Infarction 51 (ATLAS-ACS 2 TIMI 51) trial: A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome

• Published in: The American heart journal Vol. 161; no. 5; pp. 815 - 821.e6
• Main Authors: Gibson, C. Michael, Mega, Jessica L., Burton, Paul, Goto, Shinya, Verheugt, Freek, Bode, Christoph, Plotnikov, Alexei, Sun, Xiang, Cook-Bruns, Nancy, Braunwald, Eugene
• Format: Journal Article
• Language: English
• Published: New York, NY Mosby, Inc 01.05.2011; Mosby; Elsevier Limited
• Subjects: Acute Coronary Syndrome - diagnostic imaging; Acute Coronary Syndrome - drug therapy; Acute Coronary Syndrome - physiopathology; Acute coronary syndromes; Adolescent; Adult; Anticoagulants; Anticoagulants - administration & dosage; Aspirin; Biological and medical sciences; Biomarkers; Bone surgery; Cardiology. Vascular system; Cardiovascular; Coronary Angiography; Coronary heart disease; Double-Blind Method; Drug dosages; Electrocardiography; Factor Xa Inhibitors; Female; Follow-Up Studies; Heart; Heart attacks; Humans; Ischemia; Male; Medical sciences; Middle Aged; Morpholines - administration & dosage; Myocardial Infarction - diagnostic imaging; Myocardial Infarction - drug therapy; Myocardial Infarction - physiopathology; Myocarditis. Cardiomyopathies; Prospective Studies; Rivaroxaban; Stroke; Thiophenes - administration & dosage; Thrombolytic Therapy - methods; Treatment Outcome; Young Adult; Human; Myocardial infarction; Atlas; Addition; Cardiovascular disease; Standard; Coronary heart disease; Myocardial disease; Fibrinolysis; Standards; Design; Rivaroxaban; Randomization; Treatment; Efficiency; Placebo; Double blind study; Complication; Clinical trial; Circulatory system; Safety; Cardiology; Acute coronary syndrome

Although therapy with aspirin or aspirin plus a thienopyridine reduces the incidence of long-term adverse cardiovascular events among patients with acute coronary syndrome (ACS), there remains a significant residual risk of cardiovascular death, recurrent myocardial infarction (MI), and stroke. In a...